North Sea Therapeutics
Trending Articles
Related Content
Media
NorthSea Therapeutics secures €25m funding for NASH drug development
NorthSea Therapeutics (NST), a newly established Dutch biotech company, announced the completion of a €25 million Series A funding for the development of icosabutate, a structurally engineered fatty acid (SEFA) as a novel, oral approach for the treatment of non-alcoholic steatohepatitis (NASH)